VYNE Stock Overview
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.
VYNE Therapeutics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.20|
|52 Week High||US$1.75|
|52 Week Low||US$0.19|
|1 Month Change||-24.96%|
|3 Month Change||-30.14%|
|1 Year Change||-85.32%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-98.65%|
Recent News & Updates
Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite RiskyJul 02
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash WiselyMar 19
VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash WiselyDec 03
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue ForecastsAug 13
Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its DebtJun 07
Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue ForecastsFeb 17
Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)Feb 10
What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?Jan 06
Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?Dec 08
|VYNE||US Pharmaceuticals||US Market|
Return vs Industry: VYNE underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.
Return vs Market: VYNE underperformed the US Market which returned -21.2% over the past year.
|VYNE Average Weekly Movement||8.8%|
|Pharmaceuticals Industry Average Movement||11.0%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: VYNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: VYNE's weekly volatility (9%) has been stable over the past year.
About the Company
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.
VYNE Therapeutics Inc. Fundamentals Summary
|VYNE fundamental statistics|
Is VYNE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VYNE income statement (TTM)|
|Cost of Revenue||US$3.35m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.10|
|Net Profit Margin||-437.10%|
How did VYNE perform over the long term?See historical performance and comparison